Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M186Revenue $M0.0Net Margin (%)-464,457.1Altman Z-Score45.3
Enterprise Value $M148EPS $-1.4Operating Margin %-464,457.1Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.5Pre-tax Margin (%)-464,457.1Higher ROA y-yY
Price/Book5.110-y EBITDA Growth Rate %-14.6Quick Ratio19.7Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-12.9Current Ratio19.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-58.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-62.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 7.66-10%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 7.66-48%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-18.6 view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-18.68 view
Masterson Nola EDirector 2014-09-15Buy200$14.34-46.58 view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-44.93 view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-44.69 view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-48.83 view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-57.52 view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-57.21 view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-67.77 view
Anderson KatherineCFO 2013-02-01Buy1,000$11.89-35.58 view

Press Releases about RPRX :

    Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    comment on RPRX Mar 06 2013 
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    promotes testosteron Jun 22 2011 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

    More From Other Websites
    REPROS THERAPEUTICS INC. Financials May 15 2015
    10-Q for Repros Therapeutics, Inc. May 10 2015
    Repros Reports Narrower Y/Y Loss in Q1, Pipeline in Focus - Analyst Blog May 08 2015
    What's in Store for Repros (RPRX) this Earnings Season? - Analyst Blog May 07 2015
    Repros Therapeutics reports 1Q loss May 07 2015
    Repros Therapeutics reports 1Q loss May 07 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition May 07 2015
    Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results May 07 2015
    10-K for Repros Therapeutics, Inc. May 04 2015
    Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application Apr 15 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 15 2015
    Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application Apr 15 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events Apr 13 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 08 2015
    Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog Apr 07 2015
    Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization... Apr 06 2015
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 06 2015
    Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization... Apr 06 2015
    Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog Apr 02 2015
    Lumber Liquidators, CarMax are big market movers Apr 02 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK